192 related articles for article (PubMed ID: 9922304)
21. Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and ulcers: where we stand.
Graham DY
Am J Gastroenterol; 1996 Oct; 91(10):2080-6. PubMed ID: 8855725
[TBL] [Abstract][Full Text] [Related]
22. Study of outcome after targeted intervention for peptic ulcer resistant to acid suppression therapy.
Lanas A; Remacha B; Sáinz R; Hirschowitz BI
Am J Gastroenterol; 2000 Feb; 95(2):513-9. PubMed ID: 10685760
[TBL] [Abstract][Full Text] [Related]
23. Peptic ulcer disease today.
Yuan Y; Padol IT; Hunt RH
Nat Clin Pract Gastroenterol Hepatol; 2006 Feb; 3(2):80-9. PubMed ID: 16456574
[TBL] [Abstract][Full Text] [Related]
24. [Role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users].
Shimada T; Yamagata M; Hiraishi H
Nihon Rinsho; 2007 Oct; 65(10):1824-9. PubMed ID: 17926531
[TBL] [Abstract][Full Text] [Related]
25. NSAID-induced peptic ulcers and Helicobacter pylori infection: implications for patient management.
Chan FK
Drug Saf; 2005; 28(4):287-300. PubMed ID: 15783239
[TBL] [Abstract][Full Text] [Related]
26. The relation between Helicobacter pylori and nonsteroidal anti-inflammatory drugs.
Barkin J
Am J Med; 1998 Nov; 105(5A):22S-27S. PubMed ID: 9855172
[TBL] [Abstract][Full Text] [Related]
27. Ulcer risk factors: interactions between Helicobacter pylori infection, nonsteroidal use, and age.
Schubert TT; Bologna SD; Nensey Y; Schubert AB; Mascha EJ; Ma CK
Am J Med; 1993 Apr; 94(4):413-8. PubMed ID: 8475935
[TBL] [Abstract][Full Text] [Related]
28. Changes in Helicobacter pylori status in patients with rheumatoid arthritis under non-steroidal anti-inflammatory drugs.
Moriyama T; Matsumoto T; Fuchigami T; Nakamura S; Ishikawa N; Takubo N; Yamamoto S; Oshiro Y; Nakanishi M; Tomioka K; Iida M
Scand J Gastroenterol; 2004 Feb; 39(2):111-8. PubMed ID: 15000271
[TBL] [Abstract][Full Text] [Related]
29. Assessing the efficacy of famotidine and rebamipide in the treatment of gastric mucosal lesions in patients receiving long-term NSAID therapy (FORCE--famotidine or rebamipide in comparison by endoscopy).
Yamao J; Kikuchi E; Matsumoto M; Nakayama M; Ann T; Kojima H; Mitoro A; Yoshida M; Yoshikawa M; Yajima H; Miyauchi Y; Ono H; Akiyama K; Sakurai G; Kinoshita Y; Haruma K; Takakura Y; Fukui H
J Gastroenterol; 2006 Dec; 41(12):1178-85. PubMed ID: 17287897
[TBL] [Abstract][Full Text] [Related]
30. Randomised clinical trial: esomeprazole for the prevention of nonsteroidal anti-inflammatory drug-related peptic ulcers in Japanese patients.
Sugano K; Kinoshita Y; Miwa H; Takeuchi T;
Aliment Pharmacol Ther; 2012 Jul; 36(2):115-25. PubMed ID: 22591121
[TBL] [Abstract][Full Text] [Related]
31. Mucosal erosions in longterm non-steroidal anti-inflammatory drug users: predisposition to ulceration and relation to Helicobacter pylori.
Taha AS; Sturrock RD; Russell RI
Gut; 1995 Mar; 36(3):334-6. PubMed ID: 7698687
[TBL] [Abstract][Full Text] [Related]
32. Trends in peptic ulcer pharmacotherapy.
Sivri B
Fundam Clin Pharmacol; 2004 Feb; 18(1):23-31. PubMed ID: 14748750
[TBL] [Abstract][Full Text] [Related]
33. Use of proton-pump inhibitors in complicated ulcer disease and upper gastrointestinal tract bleeding.
Howden CW
Am J Health Syst Pharm; 1999 Dec; 56(23 Suppl 4):S5-11. PubMed ID: 10597118
[TBL] [Abstract][Full Text] [Related]
34. Helicobacter pylori eradication may reduce the risk of gastroduodenal lesions in chronic NSAID users.
Russell RI
Ital J Gastroenterol Hepatol; 1997 Oct; 29(5):465-9. PubMed ID: 9494858
[TBL] [Abstract][Full Text] [Related]
35. Helicobacter pylori infection and development of gastric or duodenal ulcer in arthritic patients receiving chronic NSAID therapy. The Misoprostol Study Group.
Kim JG; Graham DY
Am J Gastroenterol; 1994 Feb; 89(2):203-7. PubMed ID: 8304304
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of lansoprazole against peptic ulcers induced by non-steroidal anti-inflammatory drugs: endoscopic evaluation of ulcer healing.
Matsukawa Y; Tomita Y; Nishinarita S; Horie T; Kato K; Arakawa Y; Ko K; Shimada H; Nakano M; Kitami Y; Kurosaka H
J Int Med Res; 1997; 25(4):190-5. PubMed ID: 9283991
[TBL] [Abstract][Full Text] [Related]
37. Helicobacter pylori infection, ABO blood group, and effect of misoprostol on gastroduodenal mucosa in NSAID-treated patients with rheumatoid arthritis.
Henriksson K; Uribe A; Sandstedt B; Nord CE
Dig Dis Sci; 1993 Sep; 38(9):1688-96. PubMed ID: 8359082
[TBL] [Abstract][Full Text] [Related]
38. Management of nonsteroidal anti-inflammatory drug-induced gastroduodenal disease by acid suppression.
Lad R; Armstrong D
Can J Gastroenterol; 1999 Mar; 13(2):135-42. PubMed ID: 10203432
[TBL] [Abstract][Full Text] [Related]
39. Non-Helicobacter pylori ulcer disease in rheumatoid arthritis patients receiving long-term NSAID therapy.
Mizokami Y; Narushima K; Shiraishi T; Otsubo T; Narasaka T; Matsuoka T
J Gastroenterol; 2000; 35 Suppl 12():38-41. PubMed ID: 10779216
[TBL] [Abstract][Full Text] [Related]
40. [Modern approach to the prevention and treatment of NSAID-gastropathy].
Drozdov VN; Kim VA; Lazebnik LB
Eksp Klin Gastroenterol; 2011; (2):106-10. PubMed ID: 21560649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
